COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference

Rhea-AI Summary

COMPASS Pathways plc (Nasdaq: CMPS), a leader in mental health care innovation, announced participation in two significant events. The first is Citi’s Biopharma Virtual Co-Panel Day on May 18, 2022, focusing on mood disorders at 11:00 am ET. The second is the HC Wainwright Global Investments Conference on May 24, 2022, at 9:00 am ET. A live audio webcast will be accessible on their Investors section, with replays available for 30 days. COMPASS is advancing psilocybin therapy for treatment-resistant depression and PTSD, having completed a landmark phase IIb trial.

LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

• Citi’s Biopharma Virtual Co-Panel Day: panel “Mood Disorders/Mental Health Panel” at 11:00 am ET on 18 May 2022
• HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24 May 2022

A live audio webcast of both events will be available on the “Events” page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following each event. For more information, please visit ir.compasspathways.com.

About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Enquiries
Media: Lindsay Complin, Lindsay.Complin@compasspathways.com, +44 7702 191328
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

FAQ

When will COMPASS Pathways participate in the Citi Biopharma Virtual Co-Panel Day?

COMPASS Pathways will participate in the Citi’s Biopharma Virtual Co-Panel Day on May 18, 2022, at 11:00 am ET.

What is the date for the HC Wainwright Global Investments Conference where CMPS will present?

The HC Wainwright Global Investments Conference presentation by COMPASS Pathways is scheduled for May 24, 2022, at 9:00 am ET.

How can I access the webcasts of COMPASS Pathways' events?

The webcasts for both events will be available on the Investors section of the COMPASS Pathways website, with replays accessible for 30 days post-event.

What is COMP360 and its significance in mental health treatment by CMPS?

COMP360 is COMPASS Pathways' proprietary synthetic psilocybin formulation, designated as a Breakthrough Therapy for treatment-resistant depression by the FDA.